NASDAQ:DNLI
Denali Therapeutics Inc. Stock News
$16.16
+0.720 (+4.66%)
At Close: May 01, 2024
Dallas Fed Mfg Survey General Activity Index data reported
03:36pm, Monday, 27'th Jan 2020
Dallas Fed Mfg Survey General Activity Index data reported
Canaccord likes Biogen in premarket analyst action
01:27pm, Monday, 27'th Jan 2020
Relmada Therapeutics (NASDAQ:RLMD) initiated with Buy rating and $75 (73% upside) price target at Jefferies.Biogen (NASDAQ:BIIB) upgraded to Buy with a $360 (29% upside) price target at Canaccord Genu
Flagship Pioneering Announces Ohana Biosciences
11:05am, Monday, 27'th Jan 2020
Flagship Pioneering, a unique life sciences innovation enterprise, today announced a first-in-category reproductive health company, Ohana Biosciences. Ohana is embarking on a fresh approach to the fie
Axsome (AXSM) Completes Patient Randomization in TRD Study
02:34pm, Thursday, 23'rd Jan 2020
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
Axsome (AXSM) Completes Patient Randomization in TRD Study
02:34pm, Thursday, 23'rd Jan 2020
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
03:00pm, Wednesday, 22'nd Jan 2020
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Evoke Pharma's NDA Resubmission for Gimoti Gets FDA Acceptance
03:00pm, Wednesday, 22'nd Jan 2020
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Denali Therapeutics Sees Hammer Chart Pattern: Time to Buy?
11:11am, Wednesday, 15'th Jan 2020
Denali Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results From Its LRRK2 Program for Parkinson’s Disease
02:00pm, Tuesday, 14'th Jan 2020
LRRK2 inhibitor DNL201 Phase 1b demonstrated high levels of target and pathway engagement and improvement of lysosomal biomarkers in patients with Parkinson’s disease LRRK2.
Denali Therapeutics (NASDAQ:DNLI) Is In A Strong Position To Grow Its Business
04:01pm, Tuesday, 31'st Dec 2019
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
